Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAGE-A3 ASCI + Poly IC:LC
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intramuscular
01
Overview
MAGE-A3 ASCI + Poly IC:LC is a combination immunotherapeutic regimen designed for cancer treatment, particularly melanoma and multiple myeloma. The therapy consists of a recombinant MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI), which targets the tumor-associated antigen MAGE-A3, combined with the adjuvant Poly IC:LC (Hiltonol), a synthetic double-stranded RNA that acts as an agonist of Toll-like receptor 3 (TLR3). The combination aims to enhance anti-tumor immune responses by stimulating both innate and adaptive immunity. Clinical trials have evaluated its safety and immunogenicity in patients with melanoma and multiple myeloma, showing that it can induce robust vaccine-specific T-cell responses when used alongside other agents such as GM-CSF[1][2][4][5]. The developer for the recombinant MAGE-A3 component is GSK.
- Brand names
- Hiltonol
- Other names
- Hiltonol (for Poly IC:LC)GL-0817 (for MAGE-A3 peptide vaccine)
02
Targets
IFIH1 (MDA5)γδ TCR (T-cell receptor)TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on MAGE-A3 ASCI + Poly IC:LC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAGE-A3 ASCI + Poly IC:LC.